Last Update: Jun 01, 2026 A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan on Disease Management, Treatment-Related Outcomes and Healthcare Resource Utilization for Adult Patients With Paroxysmal Nocturnal Hemoglobinuria in China ClinicalTrials.gov Identifier: [NCT06931691](https://clinicaltrials.gov/ct2/show/NCT06931691) Novartis Reference Number:CLNP023C1CN01 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The implementation of new standards for the management of PNH and the use of iptacopan in patients with PNH are expected to change the treatment landscape and improve the overall prognosis of patients. Based on these backgrounds, we plan to conduct a real-world study of iptacopan to further evaluate its impact on treatment-related outcomes, disease management, and healthcare resource utilization in Chinese patients with PNH. Condition Paroxysmal Nocturnal Hemoglobinuria Overall Status Recruiting Number of Participants80 Start Date Jun 10, 2025 Completion Date Apr 21, 2027 Gender All Age(s) 18 Years - 80 Years (Adult, Older Adult) ## Interventions Drug ### LNP023 Capsules for oral administration ## Eligibility Criteria Inclusion criteria For Cohort 1, Patient who meets all the following criteria can be included in this study: 1\. Age ≥ 18 years at the time of signing the ICF; 2\. Patient with a documented diagnosis of PNH; 3\. Patient who has never received complement inhibitor therapy; 4\. Patient who is initiating iptacopan therapy; Patient who is initiating iptacopan therapy must start the first dose within 60 days of signing the ICF; 5\. Documented vaccination against Neisseria meningitidis and Streptococcus pneumoniae and the date of vaccination must be at least 2 weeks prior to the date of iptacopan initiation; If an urgent prescription for Iptacopan is needed, it is recommended that the antibiotic be used continuously according to the drug label until 14 days after the vaccination is completed, and that the vaccination be completed as soon as possible. 6\. Patient who has signed the ICF. For Cohort 2, Patient who meets all the following criteria can be included in this study: 1\. Age ≥ 18 years at the time of signing the ICF; 2\. Patient with a documented diagnosis of PNH; Patients who have been receiving stable treatment with C5 complement inhibitors for at least three months prior to enrollment; 3\. Patient who is initiating iptacopan therapy; Patient who is initiating iptacopan therapy must start the first dose within 60 days of signing the ICF; 4\. Documented vaccination against Neisseria meningitidis and Streptococcus pneumoniae and the date of vaccination must be at least 2 weeks prior to the date of iptacopan initiation; 5\. If an urgent prescription for Iptacopan is needed, it is recommended that the antibiotic be used continuously according to the drug label until 14 days after the vaccination is completed, and that the vaccination be completed as soon as possible. 6\. Patient who has signed the ICF. Exclusion criteria For Cohort 1 and Cohort 2, patients who meet any of the following criteria will meet the exclusion criteria for this study: 1\. Participating in an interventional PNH clinical study; 2\. Have an active systemic bacterial, viral (incl. COVID-19) or fungal infection within 14 days prior to first dose; 3\. Documented with a history of recurrent invasive infections, e.g. active systemic bacterial, viral or fungal infection within 14 days prior to first dose; 4\. Documented with a history of HIV infection; 5\. Women who are pregnant or breastfeeding or intending to conceive during the study period; 6\. Existence of bone marrow failure (reticulocytes \\< 100 × 109/L, platelets \\< 30 × 109/L, and neutrophils \\< 0.5 × 109/L) determined by the investigator; 7\. Other conditions that are not suitable for participating in the study, in the judgment of the investigator. China #### Novartis Investigative Site Recruiting Tianjin,300052,China #### Novartis Investigative Site Recruiting Guangzhou,Guangdong,510000,China #### Novartis Investigative Site Recruiting Shijiazhuang,Hebei,050000,China #### Novartis Investigative Site Recruiting Zhengzhou,Henan,450008,China #### Novartis Investigative Site Recruiting Wuhan,Hubei,430030,China #### Novartis Investigative Site Recruiting Nanchang,Jiangxi,330006,China #### Novartis Investigative Site Recruiting Changchun,Jilin,130021,China #### Novartis Investigative Site Recruiting Tianjin,300020,China #### Novartis Investigative Site Recruiting Wuhan,430022,China #### Novartis Investigative Site Recruiting Hefei,Anhui,230022,China #### Novartis Investigative Site Recruiting Guangzhou,Guangdong,510080,China #### Novartis Investigative Site Recruiting Zhengzhou,Henan,450003,China #### Novartis Investigative Site Recruiting Nantong,Jiangsu,226000,China #### Novartis Investigative Site Recruiting Jinan,250012,China ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: